Home

AtriCure, Inc. - Common Stock (ATRC)

34.13
-0.98 (-2.78%)
NASDAQ · Last Trade: Aug 1st, 12:45 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close35.10
Open35.01
Bid34.10
Ask34.15
Day's Range33.63 - 35.23
52 Week Range20.20 - 43.11
Volume208,045
Market Cap1.57B
PE Ratio (TTM)-44.32
EPS (TTM)-0.8
Dividend & YieldN/A (N/A)
1 Month Average Volume595,936

Chart

About AtriCure, Inc. - Common Stock (ATRC)

Atricure Inc is a medical device company that focuses on creating innovative solutions for the treatment of atrial fibrillation and other cardiac conditions. The company develops and manufactures specialized devices and technologies designed for minimally invasive surgical procedures, aiming to improve patient outcomes and enhance the efficiency of surgical practices. Atricure's products are utilized by healthcare professionals in various clinical settings, providing effective treatments that address the complexities of heart rhythm disorders. Through continuous research and development, the company strives to advance the field of cardiac care and contribute to the betterment of patient health. Read More

News & Press Releases

AtriCure (ATRC) Q2 Revenue Jumps 17%fool.com
Via The Motley Fool · July 30, 2025
Why LendingClub Shares Are Trading Higher By Around 23%; Here Are 20 Stocks Moving Premarketbenzinga.com
Via Benzinga · July 30, 2025
12 Health Care Stocks Moving In Tuesday's After-Market Sessionbenzinga.com
Via Benzinga · July 29, 2025
What's going on in today's after hours sessionchartmill.com
Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session.
Via Chartmill · July 29, 2025
Earnings Scheduled For July 29, 2025benzinga.com
Via Benzinga · July 29, 2025
Earnings Scheduled For April 29, 2025benzinga.com
Via Benzinga · April 29, 2025
AtriCure Earnings Previewbenzinga.com
Via Benzinga · April 28, 2025
AtriCure Reports Second Quarter 2025 Financial Results; Raises Financial Outlook for 2025
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced second quarter 2025 financial results.
By AtriCure, Inc. · Via Business Wire · July 29, 2025
AtriCure to Participate in the Canaccord Genuity 45th Annual Growth Conference
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Canaccord Genuity 45th Annual Growth Conference.
By AtriCure, Inc. · Via Business Wire · July 28, 2025
AtriCure Completes Enrollment in LeAAPS Clinical Trial for Stroke Prevention
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced the completion of enrollment in the left atrial appendage exclusion for prophylactic stroke reduction (LeAAPS) clinical trial (NCT05478304). Initiated in January 2023, LeAAPS enrolled 6,500 patients across 137 centers globally.
By AtriCure, Inc. · Via Business Wire · July 15, 2025
Earnings Scheduled For February 12, 2025benzinga.com
Via Benzinga · February 12, 2025
Expert Outlook: AtriCure Through The Eyes Of 5 Analystsbenzinga.com
Via Benzinga · February 10, 2025
AtriCure to Announce Second Quarter 2025 Financial Results
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its second quarter 2025 financial results on Tuesday, July 29, 2025.
By AtriCure, Inc. · Via Business Wire · July 8, 2025
AtriCure to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Goldman Sachs 46th Annual Global Healthcare Conference.
By AtriCure, Inc. · Via Business Wire · May 23, 2025
14 Analysts Assess AtriCure: What You Need To Knowbenzinga.com
Via Benzinga · April 30, 2025
Deep Dive Into AtriCure Stock: Analyst Perspectives (9 Ratings)benzinga.com
Via Benzinga · January 22, 2025
Visa To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Wednesdaybenzinga.com
Via Benzinga · April 30, 2025
AtriCure Reports First Quarter 2025 Financial Results
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced first quarter 2025 financial results.
By AtriCure, Inc. · Via Business Wire · April 29, 2025
AtriCure Announces First Use of the AtriClip PRO-Mini® Device
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced the first use of the newest AtriClip ® device for minimally invasive concomitant procedures, the AtriClip PRO-Mini® LAA Exclusion System. The AtriClip PRO-Mini device received FDA 510K clearance earlier this year and is a testament to AtriCure’s commitment to innovating the lowest profile and most effective surgical LAA devices on the market.
By AtriCure, Inc. · Via Business Wire · April 10, 2025
AtriCure to Announce First Quarter 2025 Financial Results
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its first quarter 2025 financial results on Tuesday, April 29, 2025.
By AtriCure, Inc. · Via Business Wire · April 8, 2025
11 Analysts Have This To Say About AtriCurebenzinga.com
Via Benzinga · March 21, 2025
AtriCure to Host Analyst & Investor Day on March 26, 2025
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today reaffirmed that the company will host an Analyst & Investor Day at its headquarters in Mason, Ohio on Wednesday, March 26, 2025 from 1:00 pm to 4:00 pm ET.
By AtriCure, Inc. · Via Business Wire · March 12, 2025
AtriCure Reports Fourth Quarter 2024 and Full Year 2024 Financial Results
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced fourth quarter 2024 and full year 2024 financial results.
By AtriCure, Inc. · Via Business Wire · February 12, 2025
Apple To $183? Here Are 10 Top Analyst Forecasts For Wednesdaybenzinga.com
Via Benzinga · January 22, 2025
AtriCure to Announce Fourth Quarter and Full Year 2024 Financial Results
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its fourth quarter and full year 2024 financial results on Wednesday, February 12, 2025.
By AtriCure, Inc. · Via Business Wire · January 22, 2025